Globality Recognized for Second Year in a Row for Best Company Culture, Best CEO, Best Company for Women and Best Company for Diversity in 2021 Comparably Awards
Globality, the company transforming the way global enterprises buy services with its leading AI-powered digital solution, has again been ranked as one of the top companies for four categories: Best Company Culture, Best CEO, Best Company for Women and Best Company for Diversity in Comparably’s 2021 Awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005196/en/
(Graphic: Business Wire)
Each quarter Comparably honors companies with Best Places to Work Awards, as rated by their own employees, across a variety of categories. The Best Company Culture ranking is an aggregation of 20 core metrics, including team leadership, career growth, work–life balance, and perks and benefits.
“Receiving all four awards from Comparably for the second successive year is a testament to the open, innovative and inclusive culture that our leadership team is committed to building at Globality, where every individual can thrive,” said Chief Human Resources Officer Sonia Mathai.
“Out of thousands of companies, Globality is once again among the top-rated best places to work,” said Comparably CEO Jason Nazar. “The organization’s high rankings in every category are a testament to Joel Hyatt’s strong people-first leadership and the organization’s commitment to workplace culture, diversity, and the inclusivity of all employee voices.”
“We are especially proud of this recognition in the midst of a very challenging year when companies are struggling with unprecedented changes to the workforce including the Great Resignation,” added Mathai. “Globality has prioritized the employee experience and engagement with our people as we continue with our mission to help build a fairer, more inclusive global economy.”
Globality lives its mission daily, with employees that represent every corner of the world working together to help create a level playing field that gives all companies, no matter their size or location, an opportunity to compete and win based on the merits of proven performance, expertise, and passion.
About Globality
Globality is a Silicon Valley-headquartered technology company co-founded by Joel Hyatt and Lior Delgo to revolutionize how companies buy and sell services. Through its AI-powered Platform and marketplace, Globality is bringing digital transformation to the sourcing industry. Globality’s AI digital solution replaces the archaic analog Request for Proposal, efficiently and effectively scoping needs, managing demand, matching companies with outstanding suppliers that meet their specific service needs and cutting the sourcing process from months to hours while delivering savings of 20% or more. In January 2021, Globality raised $138 million from Sienna Capital and the SoftBank Vision Fund, bringing the total investment it has raised since its founding six years ago to $310 million. For more information, visit www.globality.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005196/en/
Contact information
Nardi Media for Globality (US)
Justin Goldstein
justin@nardimedia.com
Missive for Globality (UK)
James Gullis
james.gullis@missive.co.uk
Globality
media@globality.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 14:00:00 EET | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence cohort for early-stage breast cancer,” said William Audeh, M.D., Chief Medical Officer at Agendia. “These results underscore our commitment to generating robust clinical evi
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 14:00:00 EET | Press release
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an older adult population, a demographic historically underrepresented in clinical trials. Bringing Precision Oncology to Older Individuals with HER2+ Disease Despite the growing number of older adults diagnosed with HER2-positive early breast cancer, optimal treatment strategies remain unclear. Many face increased risks of chemotherapy-related toxicit
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 months,” said Kabir Nath, Chief Executive Officer at Compass Pathways. “We are accelerating commercial launch plans to match this new expected timeline with the goal of advancing our mission of transforming the mental health landscape and how patients living with depression are treated.” Business Highlights COMP360 psilocybin treatment in TRD (Treatment Resistant Depression) Second Phase 3 trial, COMP006, has completed enrollment (n=585) In June 2025, we announced achievement of the 6-week primary endpoint in the first of two phase 3
TELEO Capital Closes Oversubscribed TELEO Capital II at $350 Million Hard Cap4.11.2025 13:00:00 EET | Press release
TELEO Capital Management, LLC (“TELEO”), an operationally focused private equity firm focused on investing in lower middle market enterprise software companies, today announced the final close of TELEO Capital II (“Fund II”) at its hard cap of $350 million in Limited Partner capital commitments. Fund II was oversubscribed and attracted a diverse group of new and existing institutional investors. TELEO executes a time-tested strategy in the lower middle market, leveraging a large purpose-built team and repeatable process designed to deliver consistent, outsized returns. Fund II will continue TELEO’s focus on acquiring mission-critical software divisions of large corporations. TELEO is an ideal partner to large corporate sellers in need of a solution where speed and certainty to close, minimal post-closing distraction risk from shared services agreements, and a commitment to protecting customer and employee relationships are extremely important. “We are honored by the trust our investors
Celonis Partners with Databricks to Power Enterprise AI that Continuously Improves Business Operations4.11.2025 12:00:00 EET | Press release
Celonis, a global leader in Process Intelligence, today announced a partnership with Databricks, the Data and AI company, to provide customers with a seamless, powerful pathway to operationalize AI. The integration leverages Delta Sharing to directly connect the Celonis Process Intelligence Platform with the Databricks Data Intelligence Platform. Delta Sharing is Databricks’ open source approach that enables customers to share live data across platforms, clouds and regions with strong security and governance. This bi-directional integration, powered by Delta Sharing, eliminates the need to move or copy data between the two platforms. It breaks down data silos, reduces data copies, limits synchronization errors, enhances security, and simplifies data governance. With data and process intelligence flowing freely between the two platforms, customers get a continuous learning loop for AI-driven operations. Customers can use Celonis to read live data stored in Databricks and enrich it with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom